Citations

Showing 10 of 108119 citations.

0972 Bridging the Gap of Sleep Training for Medical Learners
Dare, David M., Walsh, Meghan M., Irfan, Muna, Dare, David

Mayo Clinic

Sleep | April 13, 2019 | Volume: 42 | Issue: Supplement_1 | Pages: A391-A391

10.1093/sleep/zsz067.969 Get It

Tendon transfers for rotator cuff pathologies
Wagner, Eric R. , Elhassan, Bassem T. , Wagner, Eric R

Mayo Clinic

Current Orthopaedic Practice | April 13, 2019 | Volume: 30 | Issue: 3 | Pages: 192-199

10.1097/bco.0000000000000757 Get It

Irreparable rotator cuff tears remain one of the most challenging pathologies faced by shoulder surgeons. In both irreparable anterior (subscapularis) and posterosuperior (supraspinatus and infraspinatus) tears, patients experience marked shoulder dysfunction and pain. In this article, we review the surgical considerations for treating patients with these tears, as well as the tendon transfer options. Irreparable rotator cuff tears are associated with advanced fatty infiltration, tendon retraction, and loss of tendon length. Although there are multiple reconstructive options, most are limited to small series with short-term follow-up. Tendon transfers have emerged as very promising reconstructive options for these patients. When considering the ideal tendon transfer, it is critical to consider the four-tendon transfer principles, as well as the ability of patients to retrain the new transfer to perform a different function. The historical option for posterosuperior tears involved a latissimus dorsi transfer, while the lower trapezius transfer emerged in recent years. The historical transfer for irreparable subscapularis tears was the pectoralis major transfer, while the latissimus dorsi emerged in recent years. Further comparative trials with large patient numbers and longer follow-up are needed to better understand the indications for each of these transfers to treat these difficult pathologies.
Sarcopenia Predicts Post-transplant Mortality in Acutely Ill Men Undergoing Urgent Evaluation and Liver Transplantation
Kuo, Selena Z., Ahmad, Myra , Dunn, Michael A. , Carey, Elizabeth J. , Lin, Shezhang , Moghe, Akshata , Chen, Hui-Wei, Montaño‐Loza, Aldo J. , Ebadi, Maryam , Lai, Jennifer C.

Mayo Clinic

Transplantation | April 13, 2019 | Volume: 103 | Issue: 11 | Pages: 2312-2317

10.1097/tp.0000000000002741 | PMID 30985575 Get It

Background. We examined the association between sarcopenia and post-transplant mortality in acutely ill inpatients with cirrhosis who underwent urgent liver transplantation. Methods. Included were inpatients at 4 centers who were urgently listed as nonstatus 1 and transplanted from 2005 to 2017 with an abdominal computed tomography scan <90 days before transplantation. Skeletal muscle index (SMI) = total skeletal muscle cross-sectional area at the L3 vertebral level, normalized to height. Cox regression associated SMI with post-transplant mortality. Optimal search identified SMI cutoffs to detect survival. Results. Of 126 inpatients, 63% were male patients, model for end-stage liver disease (MELDNa) was 32, and follow up was 5.1 years. Among men, 23% died. Median SMI was lower in men who died versus survived (45 versus 51 cm2/m2). SMI was associated with post-transplant mortality (hazard ratio [HR] = 0.96 per cm2/m2, 95% CI 0.92-0.99). Patients with SMI ≤ 48 cm2/m2 versus >48 cm2/m2 experienced higher rates of death at 1 year (86% versus 95%) and 3 years (73% versus 95%) (Log-rank P = 0.01). In MELD-adjusted analysis, sarcopenia was strongly associated with post-transplant mortality (HR = 4.39, 95% CI 1.49-12.97). Among women, 35% died. Median SMI was similar in women who died versus survived (45 versus 44 cm2/m2). SMI was not associated with post-transplant mortality (HR = 1.02, 95% CI 0.96-1.09). Optimal search did not identify any SMI cutoff that predicted post-transplant mortality. Conclusions. Among patients who underwent urgent inpatient evaluation and liver transplantation, we identified an SMI cutoff value of 48 cm2/m2 to predict post-transplant mortality in men. Our data support the use of SMI as a tool to capture the impact of muscle depletion on post-transplant mortality in acutely ill men with cirrhosis undergoing urgent liver transplantation.
Methadone-Related Delirium
Westermeyer, Joseph , Thuras, Paul , Yoon, Gihyun , Batres‐y‐Carr, Tegan, Dimitropoulos, Erica, Kolla, Bhanu Prakash

Mayo Clinic

Journal of Nervous & Mental Disease | April 13, 2019 | Volume: 207 | Issue: 5 | Pages: 371-377

10.1097/nmd.0000000000000978 | PMID 30958424 Get It

Abstract Goals consist of determining 5-year prevalence and recurrence of methadone-related delirium (MRD), along with causes, treatments, and outcomes. Sample comprised 81 patients in methadone maintenance treatment. Criteria for MRD encompassed delirium with high methadone serum levels plus alleviation of delirium upon lowering methadone serum levels. MRD occurred in 14 cases who had 25 episodes. MRD precipitants included physician prescribing (i.e., excessive methadone or medications slowing methadone metabolism), drug misuse, and renal-fluid alterations. Social affiliation (housing with family, intimate partner) reduced MRD; employment increased MRD. Recovery occurred in 23/25 episodes of MRD; two episodes progressed to dementia. Obtaining serum methadone levels fostered prompt recognition.
Can Methods Developed for Interpreting Group-level Patient-reported Outcome Data be Applied to Individual Patient Management?
King, Madeleine , Dueck, Amylou C. , Revicki, Dennis A. , Dueck, A. C.

Mayo Clinic

Medical Care | April 13, 2019 | Volume: 57 | Issue: Suppl 1 | Pages: S38-S45

10.1097/mlr.0000000000001111 | PMID 30985595 Get It

Background: Patient-reported outcome (PRO) data may be used at 2 levels: to evaluate impacts of disease and treatment aggregated across individuals (group-level) and to screen/monitor individual patients to inform their management (individual-level). For PRO data to be useful at either level, we need to understand their clinical relevance. Purpose: To provide clarity on whether and how methods historically developed to interpret group-based PRO research results might be applied in clinical settings to enable PRO data from individual patients to inform their clinical management and decision-making. Methods: We first differentiate PRO-based decision-making required at group versus individual levels. We then summarize established group-based approaches to interpretation (anchor-based and distribution based), and more recent methods that draw on item calibrations and qualitative research methods. We then assess the applicability of these methods to individual patient data and individual-level decision-making. Findings: Group-based methods provide a range of thresholds that are useful in clinical care: some provide screening thresholds for patients who need additional clinical assessment and/or intervention, some provide thresholds for classifying an individual’s level of severity of symptoms or problems with function, and others provide thresholds for meaningful change when monitoring symptoms and functioning over time during or after interventions. Availability of established cut-points for screening and symptom severity, and normative/reference values, may play into choice of PRO measures for use in clinical care. Translatability of thresholds for meaningful change is more problematic because of the greater reliability needed at the individual-level versus group-level, but group-based methods may provide lower bound estimates. Caution is needed to set thresholds above bounds of measurement error to avoid “false-positive changes” triggering unwarranted alerts and action in clinic. Conclusions: While there are some challenges in applying available methods for interpreting group-based PRO results to individual patient data and clinical care—including myriad contextual factors that may influence an individual patient’s management and decision-making—they provide a useful starting point, and should be used pragmatically.
A Case Management System for Integrating Patient-reported Outcome Assessment in Clinical Practice
Zahrieh, David , Alexander, Alex , Fruth, Briant, Tan, Angelina D., Warsame, Rahma , Croghan, Katrina, Sloan, Jeff A. , Le‐Rademacher, Jennifer

Mayo Clinic

Medical Care | April 13, 2019 | Volume: 57 | Issue: Suppl 1 | Pages: S73-S79

10.1097/mlr.0000000000001095 | PMID 30985599 Get It

Introduction: What if you could only ask one question of the patient during a clinic visit? Further, suppose the patient’s biggest concern can pragmatically be incorporated into routine clinical care and clinical pathways that can address the patient’s single biggest concern can be identified. If the principal concern can be dealt with efficiently at each visit through key stakeholder case management, positive outcomes should result. Therefore, motivated by the need for patient-centered health care visits, the Beacon electronic patient-reported outcomes (PRO) quality of life (QOL) tool was developed. Methods: Central to the tool is that at each health care visit, the patient’s biggest concern is electronically communicated to the health care team. Therefore, the tool can help catalyze important discussions between the health care team and the patient, perhaps on topics that would not have been discussed otherwise at a routine visit. In recognition of the community of resources needed to provide comprehensive care, the tool generates clinical pathways or actions that can be pursued to address the patient’s biggest concern. The concern is efficiently triaged such that members of the health care community with appropriate expertise and resources are identified to address and manage that single biggest concern signaled by the patient. A report, which can be uploaded into the patient’s medical chart, is created and provides a list of resources for a case manager to assist the patient and contains graphical presentations of the patient’s QOL and a history of prior concerns. The report also labels potentially significant changes in QOL. Discussion: The tool, which has been applied successfully in several health conditions, acts as a beacon to health care providers so that a patient’s self-reported concern can be consistently and effectively integrated into their care. Key Points: It is impractical to try to deal with every patient concern in every visit. The key to the Beacon tool is that at each visit the patient’s biggest concern is identified, clinical pathways indicated, and resources efficiently matched to address the patient’s biggest concern.
What Is the Skull Structure Influence of Squamosal Suture Synostosis in Nonsyndromic and Syndromic Crouzon Craniosynostosis?
Lu, Xiaona , Chen, Guocheng, Forte, Antonio J. , Cabrejo, Raysa, Singh, Anusha , Gabrick, Kyle S., Steinbacher, Derek M., Alperovich, Michael , Alonso, Nivaldo , Persing, John A. , Forte, Antonio Jorge , Chen, Guocheng

Mayo Clinic

Journal of Craniofacial Surgery | April 13, 2019 | Volume: 30 | Issue: 6 | Pages: 1671-1675

10.1097/scs.0000000000005396 | PMID 30950948 Get It

Background: The morphologic effect of squamosal synostosis has not been clarified, due to its low occurrence rate, and its inclination to be combined with premature closure of other major sutures, especially in syndromic synostosis. This study's goal is to explore the morphological influence of squamosal synostosis in both syndromic and nonsyndromic craniosynostosis patients. Methods: Twenty-five computed tomography (CT) scans from nonsyndromic squamosal synostosis (NSS), Crouzon syndrome with squamosal synostosis (CSS), Crouzon syndrome without squamosal synostosis, and normal controls were included. Three-dimensional (3D) cephalometry, entire cranial volume and cranial fossa volume were measured using Materialise software. Results: The entire cranial volume of all groups was similar. The NSS developed a gradual reduction in the severity of reduced segmental volume from the anterior cranial fossa, to the middle cranial fossa, and to the unaffected volume of posterior cranial fossa. The CSS developed the most severe volume reduction of middle cranial fossa (12608.30 ± 2408.61 mm3 vs 26077.96 ± 4465.74 mm3, 52%), with proportionate volume reduction of the anterior (7312.21 ± 2435.97 mm3 vs 10520.63 ± 2400.43 mm3, 30%) and posterior cranial fossa (33487.29 ± 5598.93 mm3 vs 48325.04 ± 14700.44 mm3, 31%). The NSS developed a narrower anterior cranial fossa, a clockwise rotated Frankfort horizontal plane, and a retracted chin (pogonion). Conclusion: Squamosal synostosis may alter the development of cranial fossa volume, especially the volume of middle cranial fossa. However, the development of cranial base, and related facial features are determined largely by major vault sutures and associated syndromic conditions, rather than the squamosal suture alone. Level of Evidence: II
0495 Sleep Medicine and the Hospitalized Patient: Evaluation and Predictors for Sleep Disordered Breathing Testing and Associated Outcomes
Orbea, Cinthya Peña, Dupuy-McCauley, Kara , Shaughnessy, Gaja F., Louis, Erik K. St. , Morgenthaler, Timothy I.

Mayo Clinic

Sleep | April 13, 2019 | Volume: 42 | Issue: Supplement_1 | Pages: A198-A198

10.1093/sleep/zsz067.493 Get It

0142 The Cumulative Effect of Partial Chronic Sleep Restriction on the Neural Processing Stream in Neurologically Normal Individuals
Westerland, Sarah M., Linn‐Evans, Maria E. , Timm, Paul, Sandness, David J., Dueffert, Lucas G., Feemster, John, Teigen, Luke, Covassin, Naima , Svatikova, Anna , Ruzek, Lucas, Bukartyk, Jan , Gossard, Thomas , McCarter, Stuart J. , Somers, Virend K. , Louis, Erik K. St.

Mayo Clinic

Sleep | April 13, 2019 | Volume: 42 | Issue: Supplement_1 | Pages: A58-A59

10.1093/sleep/zsz067.141 Get It